Published in Obstet Gynecol on April 01, 1974
Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer. Cochrane Database Syst Rev (2011) 0.78
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett (2001) 2.86
The intrauterine device: three years of clinical experience. Fertil Steril (1968) 2.11
Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol (1974) 2.08
Vaginal cancer after maternal treatment with synthetic estrogens. N Engl J Med (1971) 2.07
Staging laparotomy in early ovarian cancer. JAMA (1983) 2.02
Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer (1989) 2.00
Patterns of metastasis in uterine sarcoma. An autopsy study. Cancer (1989) 1.89
Perineal talc exposure and subsequent epithelial ovarian cancer: a case-control study. Obstet Gynecol (1999) 1.60
Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol (1997) 1.50
Survival in patients with paraaortic lymph node metastases from endometrial adenocarcinoma clinically limited to the uterus. Int J Radiat Oncol Biol Phys (1993) 1.49
Severe radiation morbidity in carcinoma of the cervix: impact of pretherapy surgical staging and previous surgery. Int J Radiat Oncol Biol Phys (1995) 1.47
Structural preferences of beta-galactoside-reactive lectins on Actinomyces viscosus T14V and Actinomyces naeslundii WVU45. Infect Immun (1983) 1.47
p53, c-erbB, and Ki-67 expression in ovaries removed prophylactically from women with a family history of ovarian cancer. Int J Gynecol Pathol (1999) 1.42
Age at onset of ovarian cancer in women with a strong family history of ovarian cancer. Gynecol Oncol (1997) 1.39
Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols. J Med Chem (1981) 1.34
Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev (2001) 1.32
Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol (1998) 1.27
A case-control study of milk-drinking and ovarian cancer risk. Am J Epidemiol (1990) 1.26
Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstet Gynecol (1975) 1.19
The accuracy of lymphangiography in carcinoma of the uterine cervix. Am J Roentgenol Radium Ther Nucl Med (1971) 1.19
Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol (1998) 1.17
Pulmonary hypertrophic osteoarthropathy, spider angiomata, and estrogen hyperexcretion in neoplasia. Ann Intern Med (1969) 1.13
Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol (1999) 1.13
Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. Int J Radiat Oncol Biol Phys (1997) 1.12
Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol (1999) 1.12
Monoclonal antibodies recognizing tumor-associated antigen of human ovarian mucinous cystadenocarcinomas. Cancer Res (1982) 1.12
Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer (2004) 1.10
The cardiovascular acitivity of ICI 118,587 a novel beta-adrenoceptor partial agonist [proceedings]. Br J Pharmacol (1979) 1.09
Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol (1999) 1.09
Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol (1978) 1.07
The value of lymphangiography in malignant disease of the uterine cervix. Radiology (1972) 1.06
Mutations in BRCA1 from fixed, paraffin-embedded tissue can be artifacts of preservation. Cancer Genet Cytogenet (1998) 1.06
Isolation and morphologic characterization of human ovarian carcinoma cell clusters present in effusions. Exp Cell Biol (1987) 1.05
Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer (1980) 1.03
Laparoscopic surgery in obese women. Obstet Gynecol (1999) 1.00
Familial ovarian cancer. Gynecol Oncol (1979) 0.99
Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol (2000) 0.99
Estradiol production after ovariectomy for carcinoma of the breast. N Engl J Med (1969) 0.99
Preliminary trial of aminoglutethimide in breast cancer. Cancer (1973) 0.99
Extraovarian primary peritoneal carcinoma. Oncology (Williston Park) (1998) 0.98
Familial Ovarian Cancer Registry. Obstet Gynecol (1984) 0.97
A novel series of potent and selective agonists at the opioid kappa-receptor. Eur J Pharmacol (1988) 0.97
Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin Cancer Res (1999) 0.96
Improvements in pelvic exenteration: factors responsible for reducing morbidity and mortality. Ann Surg Oncol (1998) 0.96
Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. J Natl Cancer Inst (2000) 0.95
Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet Cytogenet (1998) 0.95
Small cell carcinoma of the ovary: a rapidly lethal tumor occurring in the young. Gynecol Oncol (1985) 0.95
Substrate specificity and other properties of alpha-L-fucosidase from human serum. J Biol Chem (1982) 0.95
Enterovaginal and enterocutaneous fistulae in women with gynecologic malignancies. Obstet Gynecol (1976) 0.94
Malignant peritoneal cytology as prognostic indicator in stage I endometrial cancer. Obstet Gynecol (1983) 0.94
Fallopian tube cancer. The Roswell Park experience. Cancer (1990) 0.93
Uterine endolymphatic stromal myosis: a collaborative study. Obstet Gynecol (1984) 0.92
Immunologic studies of human serous cystadenocarcinoma of ovary. Demonstration of tumor-associated antigens. Cancer (1973) 0.92
Squamous cell carcinoma arising in ovarian endometriosis. Gynecol Oncol (1978) 0.91
Tubal ligation and the risk of ovarian carcinoma. Cancer Detect Prev (1997) 0.91
Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect. Gynecol Oncol (1999) 0.91
Tumor markers for ovarian cancer. Int Adv Surg Oncol (1979) 0.90
Ovarian carcinoma. A decade of progress. Cancer (1984) 0.90
Adriamycin and bleomycin, alone and in combination, in gynecologic cancers. Cancer (1973) 0.90
Comparison of cisplatin and carboplatin cytotoxicity in human ovarian cancer cell lines using the MTT assay. Gynecol Oncol (1990) 0.89
Five-year survival (with no evidence of disease) in patients with biopsy-confirmed aortic node metastasis from cervical carcinoma. Am J Obstet Gynecol (1981) 0.89
Peritoneal papillary carcinoma. Gynecol Oncol (1988) 0.89
Etiology, biology, and epidemiology of ovarian cancer. Semin Surg Oncol (1994) 0.89
Effects of IL-12 on human ovarian tumors engrafted into SCID mice. Gynecol Oncol (1999) 0.88
Epithelioid sarcoma of the vulva. Obstet Gynecol (1972) 0.88
Distant metastasis of adenoacanthoma of the endometrium. Am J Obstet Gynecol (1966) 0.88
Microsatellite instability in ovarian and other pelvic carcinomas. Cancer Genet Cytogenet (2000) 0.88
Uridine 5'-diphosphate-galactose:glycoprotein galactosyltransferase activity in the ovarian cancer patient. Cancer Res (1976) 0.87
Variations in retention performance during long term memory formation. Nature (1971) 0.87
Hydroxyurea: a radiation potentiator in carcinoma of the uterine cervix. A randomized double-blind study. Am J Obstet Gynecol (1983) 0.87
Paraaortic lymph node evaluation in stage I endometrial carcinoma. Obstet Gynecol (1982) 0.86
Intestinal perforation secondary to paclitaxel. Gynecol Oncol (1995) 0.86
Uterine prolapse during pregnancy. Obstet Gynecol (1968) 0.86
Laparoscopic management of women with a family history of ovarian cancer. J Surg Oncol (1999) 0.85
Glycosyltransferase and glycosidase activities in ovarian cancer patients. Cancer Res (1979) 0.85
The curative potential of radiation therapy in the treatment of primary vaginal carcinoma. Am J Clin Oncol (1996) 0.85
Expression of the p53 induced tumor suppressor p21waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int J Gynecol Pathol (1997) 0.85
Cystadenocarcinoma of the ovary in a 4-year-old: benign transformation during therapy. Cancer (1980) 0.85
Estrogen secretion, biosynthesis and metabolism: their relationship to the menstrual cycle. Steroids (1966) 0.85
Ovarian pregnancy and intrauterine device. JAMA (1967) 0.85
Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervix. Am J Obstet Gynecol (1977) 0.85
Weekly cis-diamminedichloroplatinum II as induction chemotherapy in recurrent carcinoma of the cervix. Gynecol Oncol (1984) 0.85
In vivo observations on testosterone and estradiol-17 beta protein binding in women. J Clin Endocrinol Metab (1969) 0.85
Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma. Obstet Gynecol (1986) 0.85
High dose irradiation to biopsy confirmed aortic node metastases from carcinoma of the uterine cervix. Cancer (1977) 0.85
Monilia septicemia associated with hyperalimentation. Obstet Gynecol (1971) 0.84
Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice. Gynecol Oncol (2000) 0.84
Univariate and multivariate analyses of 5-year survival, recurrence, and inguinal node metastases in stage I and II vulvar carcinoma. J Surg Oncol (1985) 0.84
Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am J Clin Oncol (1998) 0.84